NFA
ONCT

Nationwide Fund Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Nationwide Fund Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-15
Closed -$32K – 3394
2014
Q1 		$32K Hold
15
– – ﹤0.01% 2884
2013
Q4 		$35K Hold
15
– – ﹤0.01% 3086
2013
Q3 		$42K Hold
15
– – ﹤0.01% 3059
2013
Q2 		$134K Buy
+15
New +$116K ﹤0.01% 2676

Other funds holding ONCT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nationwide Fund Advisors's ONCT Position: Q2 2014 in Review

Nationwide Fund Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2014, closing a stake of 15 shares — an estimated $32K sold.

Nationwide Fund Advisors first reported a position in ONCT in Q2 2013 and held it in 4 quarters. The position peaked at $134K in Q2 2013. 50 funds tracked by Wall St. Rank hold ONCT as of Q2 2014.

  • Nationwide Fund Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Nationwide Fund Advisors sold 15 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $32K.
  • Nationwide Fund Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
  • Nationwide Fund Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $134K in Q2 2013.
  • 50 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2014.

Based on Nationwide Fund Advisors's 13F filing for Q2 2014, filed 11 Aug 2014.